Biodistribution and Tumor Targeted Accumulation of Anti-CEA-loaded Iron Nanoparticles.

IF 2.2 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current pharmaceutical biotechnology Pub Date : 2025-01-01 DOI:10.2174/0113892010268872240104114444

Thais Silva Correa, William Gustavo Lima, Aline Beatriz do Couto Campos, Alexsandro Sobreira Galdino, Emilia Celma de Oliveira Lima, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes, Mariana Campos-da-Paz

{"title":"Biodistribution and Tumor Targeted Accumulation of Anti-CEA-loaded Iron Nanoparticles.","authors":"Thais Silva Correa, William Gustavo Lima, Aline Beatriz do Couto Campos, Alexsandro Sobreira Galdino, Emilia Celma de Oliveira Lima, Valbert Nascimento Cardoso, Simone Odília Antunes Fernandes, Mariana Campos-da-Paz","doi":"10.2174/0113892010268872240104114444","DOIUrl":null,"url":null,"abstract":"Introduction: Active targeting of tumors by nanomaterials favors early diagnosis and the reduction of harsh side effects of chemotherapeuticals.Methods: We synthesized magnetic nanoparticles (64 nm; -40 mV) suspended in a magnetic fluid (MF) and decorated them with anti-carcinoembryonic antigen (MFCEA; 144 nm; -39 mV). MF and MFCEA nanoparticles were successfully radiolabeled with technetium-99m (99mTc) and intravenously injected in CEA-positive 4T1 tumor-bearing mice to perform biodistribution studies. Both 99mTc-MF and 99mTc-MFCEA had marked uptake by the liver and spleen, and the renal uptake of 99mTc-MFCEA was higher than that observed for 99mTc-MF at 20h. At 1 and 5 hours, the urinary excretion was higher for 99mTc-MF than for 99mTc-MFCEA.Results: These data suggest that anti-CEA decoration might be responsible for a delay in renal clearance. Regarding the tumor, 99mTc-MFCEA showed tumor uptake nearly two times higher than that observed for 99mTc-MFCEA. Similarly, the target-nontarget ratio was higher with 99mTc-MFCEA when compared to the group that received the 99mTc-MF.Conclusion: These data validated the ability of active tumor targeting by the as-developed anti- CEA loaded nanoparticles and are very promising results for the future development of a nanodevice for the management of breast cancer and other types of CEA-positive tumors.","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":"108-119"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010268872240104114444","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Active targeting of tumors by nanomaterials favors early diagnosis and the reduction of harsh side effects of chemotherapeuticals.

Methods: We synthesized magnetic nanoparticles (64 nm; -40 mV) suspended in a magnetic fluid (MF) and decorated them with anti-carcinoembryonic antigen (MFCEA; 144 nm; -39 mV). MF and MFCEA nanoparticles were successfully radiolabeled with technetium-99m (^99mTc) and intravenously injected in CEA-positive 4T1 tumor-bearing mice to perform biodistribution studies. Both ^99mTc-MF and ^99mTc-MFCEA had marked uptake by the liver and spleen, and the renal uptake of ^99mTc-MFCEA was higher than that observed for ^99mTc-MF at 20h. At 1 and 5 hours, the urinary excretion was higher for ^99mTc-MF than for ^99mTc-MFCEA.

Results: These data suggest that anti-CEA decoration might be responsible for a delay in renal clearance. Regarding the tumor, ^99mTc-MFCEA showed tumor uptake nearly two times higher than that observed for ^99mTc-MFCEA. Similarly, the target-nontarget ratio was higher with ^99mTc-MFCEA when compared to the group that received the ^99mTc-MF.

Conclusion: These data validated the ability of active tumor targeting by the as-developed anti- CEA loaded nanoparticles and are very promising results for the future development of a nanodevice for the management of breast cancer and other types of CEA-positive tumors.

查看原文本刊更多论文

抗癌胚抗原（CEA）负载铁纳米粒子的生物分布和肿瘤靶向积累

简介：纳米材料对肿瘤的积极靶向作用有利于早期诊断和减少化疗药物的副作用：纳米材料对肿瘤的主动靶向作用有利于早期诊断和减少化疗药物的不良副作用：我们合成了悬浮在磁性流体（MF）中的磁性纳米粒子（64 nm; -40 mV），并用抗癌胚胎抗原（MFCEA; 144 nm; -39 mV）对其进行了装饰。MF 和 MFCEA 纳米粒子成功地被锝-99m（99mTc）放射性标记，并被静脉注射到 CEA 阳性的 4T1 肿瘤小鼠体内，进行生物分布研究。肝脏和脾脏对 99mTc-MF 和 99mTc-MFCEA 均有明显摄取，20 小时后，肾脏对 99mTc-MFCEA 的摄取量高于 99mTc-MF 的摄取量。在 1 小时和 5 小时时，99m锝-MF 的尿排泄量高于 99m锝-MFCEA：这些数据表明，抗 CEA 装饰可能是导致肾清除延迟的原因。在肿瘤方面，99m锝-MFCEA 的肿瘤摄取率比 99m锝-MFCEA 高近两倍。同样，与接受99m锝-MF的组别相比，99m锝-MFCEA的靶-非靶比率更高：这些数据验证了所开发的抗 CEA 负载纳米粒子主动靶向肿瘤的能力，这对未来开发用于治疗乳腺癌和其他类型 CEA 阳性肿瘤的纳米设备是非常有前景的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current pharmaceutical biotechnology 医学-生化与分子生物学

CiteScore

5.60

自引率

3.60%

发文量

203

审稿时长

6 months

期刊介绍： Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.